Today's Top Performers In Health Care

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 13 points (0.1%) at 17,609 as of Tuesday, June 30, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,652 issues advancing vs. 1,385 declining with 154 unchanged.

The Health Care sector currently sits up 1.3% versus the S&P 500, which is unchanged. Top gainers within the sector include Intrexon ( XON), up 4.3%, Opko Health ( OPK), up 4.1%, Biomarin Pharmaceutical ( BMRN), up 2.1%, Illumina ( ILMN), up 1.7% and Gilead ( GILD), up 1.4%. On the negative front, top decliners within the sector include Cigna ( CI), down 1.2%, GlaxoSmithKline ( GSK), down 1.1%, Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.1%, Teva Pharmaceutical Industries ( TEVA), down 0.9% and Pfizer ( PFE), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. bluebird bio ( BLUE) is one of the companies pushing the Health Care sector higher today. As of noon trading, bluebird bio is up $7.86 (4.9%) to $167.13 on average volume. Thus far, 518,105 shares of bluebird bio exchanged hands as compared to its average daily volume of 869,900 shares. The stock has ranged in price between $161.50-$167.24 after having opened the day at $161.68 as compared to the previous trading day's close of $159.27.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Bluebird bio has a market cap of $5.4 billion and is part of the drugs industry. Shares are up 80.6% year-to-date as of the close of trading on Monday. Currently there are 9 analysts who rate bluebird bio a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates bluebird bio as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and weak operating cash flow. Get the full bluebird bio Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Anthem ( ANTM) is up $0.87 (0.5%) to $163.93 on average volume. Thus far, 773,627 shares of Anthem exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $163.70-$165.85 after having opened the day at $163.80 as compared to the previous trading day's close of $163.06.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial and Specialty Business, Government Business, and Other. Anthem has a market cap of $43.6 billion and is part of the health services industry. Shares are up 31.0% year-to-date as of the close of trading on Monday. Currently there are 9 analysts who rate Anthem a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Anthem as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Anthem Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Medtronic ( MDT) is up $0.53 (0.7%) to $73.83 on average volume. Thus far, 2.7 million shares of Medtronic exchanged hands as compared to its average daily volume of 5.2 million shares. The stock has ranged in price between $73.66-$74.67 after having opened the day at $74.19 as compared to the previous trading day's close of $73.30.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Medtronic plc, a healthcare solutions company, provides medical technologies, services, and solutions worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group. Medtronic has a market cap of $106.5 billion and is part of the health services industry. Shares are up 1.5% year-to-date as of the close of trading on Monday. Currently there are 13 analysts who rate Medtronic a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Medtronic Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

If you liked this article you might like

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017